Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Haematologica. 2017 Feb;102(2):e47-e51. doi: 10.3324/haematol.2016.153130. Epub 2016 Oct 27.

¹ Department of Hematology AZ St-Jan Brugge-Oostende, Belgium.
² EORTC Headquarters, Brussels, Belgium.
³ Hematology, Sapienza University, Rome, Italy.
⁴ Department of Hematology, Radboud University, Medical Center, Nijmegen, the Netherlands.
⁵ Department of Hematology, Leiden University Medical Center, the Netherlands.
⁶ Department of Hematology and of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
⁷ Department of Hematology, Istituto Europeo di Oncologia, Milan, Italy.
⁸ Jeroen Bosch Medical Center, Den Bosch, the Netherlands.
⁹ Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA), Rome, Italy.
¹⁰ Department of Hematology, Hôpital Saint-Antoine, APHP, Paris, France.
¹¹ Department of Hematology, Institut Jules Bordet, ULB, Brussels, Belgium.
¹² Department of Tumorimmunology, Radboud University, Medical Center, Nijmegen, the Netherlands.
¹³ GIGA-I3-Hematology, University of Liège, Belgium f.baron@ulg.ac.be.

No abstract available

Publication types